This panel of genes includes trefoil factor family proteins, TFF1 and TFF3, which have been shown to be upregulated in BL immunohistochemistry tumor samples from patients with HR+/HER2- mBC who experience late progression on CDK4/6i therapy [91]. This evidence concerns the gene HR and neoplasm.